Freitag, 11. November 2011

Rückblick Pharma Sales Force 2011

IQPC blickt auf ein erfolgreiches Jahresforum Pharma Sales Force 2011.

Über 130 Teilnehmer nahmen an der Pharma Sales Force 2011 teil, um sich über aktuelle Herausforderungen im Pharmavertrieb auszutauschen. Auch das Networking kam wiedermal nicht zu kurz: Der Kongress bot zahlreiche Gelegenheiten zum offenen Austausch an. Und auch im Anschluss konnten Themen und Gespräche in angenehmer Atmosphäre vertieft werden.


Mehr als 30 Fachvorträge, Round-Table-Diskussionen und Workshops zu den Themen Market Access, Marketing und Vertrieb boten die Möglichkeit zum Benchmarking der eigenen Konzepte und Strategien.

Sehen Sie hier die schönsten Eindrücke der diesjährigen Pharma Sales Force 2011 im Impressionen-Video:



Für ein gelungenes Jahresforum in 2011 dankt IQPC allen Teilnehmern, Sprechern, Sponsoren und Medienpartnern. Die Vorbereitungen für 2012 sind bereits in vollem Gange. Bis nächstes Jahr!

Mittwoch, 19. Oktober 2011

Learn more about the Drug Discovery Process

We've all been touched by the miracles of modern medicine. But few people understand how medicines are made, and the immense effort required to get them to market and into our hands.


Discovery Partnerships gives you the change to share costs, developments and challenges along the way.

Efficient drug discovery is still the key for the pharmaceutical industry to survive. With pharmaceutical companies worrying strongly about how to fasten time-to-market, effective drug discovery and enhanced prognosis become more important than ever. Therefore, many pharmaceutical companies are looking for long-term alliances and innovative ways of partnering to speed up development time and share risks.

IQPC's annual congress "Discovery Partnerships" is back. The only European event covering Early Discovery and Pre-clinical Partnerships! Be prepared for 2012 and beyond. Join the 3rd International Congress DISCOVERY PARTNERSHIPS from the 13 - 14 December 2011 in Düsseldorf, Germany.

Dieser in Englisch abgehaltene Fachkongress wird für die Fach- und Führungskräfte von pharmazeutischen Unternehmen, CROs sowie Biotechs initiiert. – Wie können erfolgreiche Partnerschaften etabliert werden? Welche Balance zwischen Risikostreuung und Kostenteilung ist vor allem bei einer Partnerschaft von KMUs und CROs optimal? Welche Vorteile bringen "2.0 Kommunikationskanäle" mit sich? – Diese und weitere Fragestellungen bilden den Rahmen des "3rd International Congress Discovery Partnerships".

Dienstag, 11. Oktober 2011

Contract research on the rise

The global economic crisis has got most businesses pinching pennies just to stay afloat, and the drug development industry is no exception. But at least one area of the biotechnology sector -- contract research organizations (CROs) -- is on the rise.

CROs first showed up in the biotech industry in the late 1970s and quickly took on a significant role in research and development (R&D), eventually expanding from drug discovery and preclinical work to clinical trials, drug manufacturing, and even marketing.

According to a 2005 Thomson CenterWatch survey, the $15 billion CRO industry was growing at a rate of 12% each year, but data from the past two years show a substantially higher annual growth rate of nearly 17%. In 2007, of the approximately $60 billion biotech and pharmaceutical companies spent on drug
development, $15 billion (25%) was outsourced. Last year, despite the economic recession, the CRO market grew to nearly $20 billion -- 29% of the $74 billion drug development budget.

Tip: 3rd International Congress Discovery Partnerships from 13 - 14 December 2011 im Radisson Blu Scandinavia in Düsseldorf, Germany
The number and depth of the connections between CROs and drug developers has grown so much, they now have their own match-making website. Last October, serial biotech entrepreneur Jae Chung started what he expected to be a simple drug development directory. Now, just three months after its late April launch, goBalto boasts more than 7000 companies and consultants, including 2,200 CROs, all of which can be searched and rated by one another. With a couple of hundred companies and consultants adding themselves each week,
"we're one of the fastest growing professional networking sites," Chung said. Finding partnerships, which used to take four to six weeks, can now take as little as two days, he claimed.

The types of partnerships that CROs make are also changing. While pharmaceutical companies used to  contract work on single projects, explained Quintiles Transnational Corp. Executive Vice President Ronald Wooten, they're now outsourcing entire programs. "The CRO really becomes a permanent supplier of certain functions." Indeed, concurred John Watson, the President of Strategic Partnering and Integrated Drug Development Group at Covance, "with all the [recent budgetary] pressure that the larger pharmaceutical companies are under, there's been a shift to more strategic outsourcing" where CROs are no longer mere service providers, but full service collaborators.

"In turbulent economic times, clients have a greater need particularly for advisory services," Josef von Rickenbach, Chairman and CEO of PAREXEL International, agreed in an email. Some CROs are even stepping in to help make starting new biotech and pharma projects a safer endeavor -- Quintiles, for example, now co-invests in some projects with their clients so as to reduce the financial risk of any single program.

More integrated partnerships can shorten the time it takes to develop new drugs, and at an average of $2 million in lost revenue per day, significantly lower costs as well. Covance, for example, claims that their services can cut the time for preclinical testing by more than half.

In addition, such dynamic partnerships serve to keep fixed costs low and "relieve [biotech and pharmaceutical companies] of the burdens and overheads of process management so they can focus on the medical, scientific, and regulatory aspects of drug development," Wooten explained. "It's all about the pharma companies wanting to be more virtual and more variable," Wooten said. For smaller biotech companies, virtuality is nothing new, but the virtual business is certainly becoming more popular during these times of economic budget crunching. Zafgen Inc., for example, an early phase biotech company focused
on developing new therapies for obesity, recently switched to outsourcing 100% of their work, including not just the drug development projects, but human resources, legal, and communication functions as well. This shift involved a staff cut of more than 50%, as well as a move to cheaper office space with no laboratories and the selling of their lab equipment. "We should all be careful about every dime we spend in biotech," said Tom Hughes, the company's president and CEO.

Despite the economic motivation for this recent restructuring, Hughes believes in enlisting the help of CROs where possible even in more lucrative times. "It's a great way to get some extra brains on the problem," he said. "There's a wealth of expertise out there that you can tap into that you would never be able to develop yourself."

Tip: Download free articles, whitepapers and presentations on Discovery Partnerships
The current CRO boom is not limited to United States. In China, in particular, the market seems to be accelerating even more rapidly. "From the end of 2007 to now, [during] the recession period globally, we do see the growth in China is stronger," said Jenny Zhang, a North America-based business development director for the Chinese company Tigermed Consulting Ltd. In addition to the big, international pharmaceutical companies setting up R&D centers in Asia, China's domestic drug companies are growing as well.

In both cases, Zhang said, this growth stems primarily from a cost advantage to doing business in China, both in physician salaries and healthcare costs, as well as what she calls the "patient advantage." In the US, patients -- especially those with health insurance -- are reluctant to participate in clinical trials. "In China," she said, "we have 1.3 billion people, [most of whom] don't have good access to the health care system." Participating in a study is often their best chance for treatment.

Both domestically and internationally, the CRO market is rapidly expanding, and while the recent economic depression may have instigated this change, outsourcing in biopharma is increasingly becoming the new way of doing business. Even when the economy bounces back, Wooten doesn't predict a reversal of this trend. If anything, he said, "I see an acceleration of it."

Source: The Scientist - Posted by Jef Akst

Freitag, 7. Oktober 2011

Konsequenzen des AMNOG für den Bestandsmarkt und für Indikationserweiterungen

Mit dem Inkrafttreten des AMNOG zum 1. Januar 2011 hat eine neue Zeitrechnung begonnen. Der Pharma-Vertrieb steht vor neuen Herausforderungen.
  • Wie sollte sich die Industrie auf Nutzenbewertungen im Bestandsmarkt vorbereiten?
  • Welche Problemstellungen gibt es bei der Zulassung neuer Anwendungsgebiete?
  • Welche konkreten Auswirkungen ergeben sich für die Vertriebsstrukturen?
Auf diese und weitere Fragen müssen Antworten gefunden werden.

Mehr zu diesem Thema erfahren Sie auf der Pharma Sales Force u.a. von Dr. Steffen Wahler, Vice President Clinical Outcome and Reimbursement bei der Iroko Cardio International Sàrl in Genf. In dieser Funktion leitet er auch den Außendienst seines Unternehmens in Deutschland, Österreich und Polen. Zuvor war er seit dem Jahr 2006 Geschäftsführer des Geschäftsbereichs „Gesundheitsökonomie” im vfa. Er studierte Humanmedizin in Hamburg, Volkswirtschaftslehre an der University of California, Santa Barbara und Gesundheitsökonomie an der University of York. Er verantwortete in leitender Funktion die Themen Gesundheits-, Vertrags- und Kostenmanagement bei mehreren gesetzlichen Krankenversicherungen und internationalen pharmazeutischen Unternehmen. Dr. med. Steffen Wahler war vier Jahre Mitglied des Kuratoriums des IQWiG.

Treffen Sie Dr. Steffen Wahler und viele andere Experten auf der Pharma Sales Force 2011 in Berlin. Mehr Informationen finden Sie hier.



Dienstag, 27. September 2011

Diskutieren Sie mit Patrick Langecker - Leiter Multichannel Management der Bayer Vital GmbH

Patrick Langecker leitet seit Januar 2011 das Team Multichannel Management bei der Bayer Vital GmbH in der Business Unit General Medicine. In diesem neu geschaffenen Team geht es um die geschäftsnahe Vernetzung aller möglichen Kommunikationskanäle zum Kunden in Ergänzung zum Außendienst. Zuvor war er zwei Jahre im Bereich Marketing and Sales Innovations als Leiter Dialogmarketing businessübergreifend tätig. Von 2005 bis 2008 war er für die Endkundenansprache im Marketing von Diabetes Care der Bayer Vital verantwortlich. Vor seiner Zeit bei Bayer arbeitete er als CRM- und Dialogexperte für internationale Konzerne im Finanzdienstleistungs-, Reise- und Automobilbereich, sowie für große Servicedienstleister.

Auf der Pharma Sales Force 2011 wird Patrick Langecker die interaktive Brainstorming Session zu Closed Loop Marketing moderieren. Nutzen Sie die Möglichkeit zum informellen Erfahrungsaustausch. Diskutieren Sie in kleinen Gruppen aktuelle Herausforderungen und Perspektiven im Pharmavertrieb und profitieren Sie vom Wissen unserer Branchenexperten. Bringen Sie eigene Ideen und Erfahrungen ein und tauschen Sie sich mit anderen Teilnehmern in einem offenen Diskussionsforum aus!

Mehr Informationen zu dem Jahresforum und den Brainstorming Sessions finden Sie hier.



Dienstag, 20. September 2011

Free whitepapers on Pharmacogenomics and Drug Transporters


Access free whitepapers on Pharma Imaging and Modelling for Optimized Translational Research; for example articles on Pharmacogenomics and Drug Transporters:


Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects
It is well recognized that different patients respond in different ways to the same medication. These differences are often greater among members of a population than they are within the same person at different times (or between monozygotic twins).

Drug Transporters in ADME
Pharmaceutical companies are investing research time into understanding and modelling of drug transporters to better predict drug-drug interactions and toxicities. Whilst understanding drug-drug interactions can enhance study efficiency and drug efficacy, the challenges presented by drug transporters are complex.

Access more at:  Imaging and Modelling for Optimized Translational Research

Montag, 19. September 2011

Video: Market Access und Stakeholder Management in der Pharmaindustrie

Isabel Henkel, Director Access & Reimbursement, Johnson & Johnson Medical GmbH, exklusiv im Interview!

Frau Henkel spricht über die neuen Aufgaben für die Pharmaindustrie im Bezug auf Market Access und Stakeholder Management sowie die vierte Hürde im deutschen Gesundheitssystem.

Sehen Sie das gesamte Video hier.



Mittwoch, 14. September 2011

Optimizing drug discovery through microdosing

Defining a microdose
The EMEA Position Paper defines the human microdose as the 1/100th of the dose calculated to yield a pharmacological effect of the compound based on primary pharmacodynamic data obtained from animal and in vitro models. According to the EMEA guidelines, the total amount of drug compound(s) being tested and administered in a human microdosing study must not exceed 100 micro grams.

Microdosing in optimizing drug discovery
Advances in areas of combinational chemistry, molecular and cell biology, high throughput technology and strong economic forces have lead to greater competition and rapid changes in nonclinical drug development. Patients, physicians and pharmaceutical sponsors alike are looking for more effective and safer medicines to be developed faster and also have improved costeffectiveness (Lesko et al., 2000).

Reigner et al. (1996) have explained that predictive power of preclinical drug metabolism has advanced due to a considerable betterment in the  understanding of the relationships between in vitro, animal and human pharmacokinetics. They further emphasize that focussed application of pharmacokinetics and pharmacodynamics has improved the efficacy of the drug development process in the pharmaceutical industry. Microdosing  has proven to be an effective method to understand the pharmacokinetic and pharmacodynamic  behaviour of new drugs in humans.

Microdosing has hastened the pharmaceutical preclinical to clinical translation involved in the drug development process. Pang, Rodrigues and Peter (2009, p. 363) elucidate that microdosing has not been developed to determine the safety or efficacy of test compounds when administered to humans. The main purpose of human microdosing studies is to determine key pharmacokinetic parameters in reaction to very small doses of a new drug being tested.

Advent of microdosing
Drug discovery is a long drawn process that involves preclinical pharmacological testing and clinical application in animals and then humans, before drugs can be certified for normal dosage and prescription. Considering the fact that microdoses help decipher the pharmacokinetics in humans for varied newly developed pharmaceutical compounds, large amount of resources in the form of time, energy and money need not be invested into a new drug candidate that is unsuccessful at this level itself.

As a matter of fact, around 40% of the newly developed drugs are withdrawn after phase 1 clinical trial because of undesirable pharmacokinetic properties (Lappin and Garner, 2003). Accordingly, a phase 0 testing has been introduced before the traditionally followed phase 1 clinical trial in humans. Through this, microdosing can be performed in human volunteers in phase 0 following minimal trials in animals. Based on the performance and pharmacokinetic behaviour during this stage, failure drugs can be easily identified and eliminated at the earlier stages without wasting much of time and energy in further drug development and testing, On the other hand, microdosing also helps identify the more promising drug compounds from a pool that could be further explored and developed to achieve desired clinical results in humans when they are tested at later stages of drug development. Sarapa (2003) highlights that two of the most important positive outcomes of performing phase 0 studies by administering microdoses to humans are the reduction in time  and resources wasted in prolonged further testing and reduced attrition during drug testing.

Concentration of microdoses
A microdose is usually 100 times less concentrated than the medication that would be administered once tested and verified. This way the concentration of the newly developed drug entering the human system would be well less than 1/100 concentration of the drug. This is less liable to produce any harm to the human volunteers during testing.

Microdosing procedure
Selecting candidates for human microdosingPharmacological activity is first studies in animal models. Based on this demonstration and minimal animal testing, it is decided whether or not to proceed with clinical trials in humans. Accordingly, candidates for the human microdosing study are selected.

>> Read more on:
  • Microdose synthesis
  • Administration of Human microdose
  • Bio analysis post microdosing
  • Advantages of Microdosing
  • Limitations of Microdosing
  • Microdosing in drug development
  • Regulations for microdosing
  • Conclusion

Download the full 7-page PDF article for free, click here.

Want to learn more about drug discovery?
Visit our Download Center for more articles, whitepapers and interviews:
http://bit.ly/preclinical-clinical-translation

Dienstag, 13. September 2011

Tackling the Challenge of Serialisation and Traceability

As counterfeit drug sales become increasingly costly to both pharmaceutical manufacturers and patients, companies are attempting to address the challenges of serialisation and traceability to reduce the burden on health services across the world. There is already a great degree of activity in the industry to help boost supply chain security, reduce counterfeiting and ultimately protect patient safety and companies' bottom lines, and one company which is aiming make a difference in the sector is Belgian firm Zetes.

The coding systems company has already is predicted a "very good financial year" after revenues rose by almost six per cent in the first half of 2010, largely due to sales in its Goods ID division, which focuses on technologies used to manage products through the supply chain using barcodes, RFID and voice recognition systems. In its interim results statement, the firm revealed that although much of Zetes Goods ID division sales come from the food sector, it has begun to make forays into the pharmaceutical sector and has ambitious plans with regards to serialisation and traceability.

"From a sector perspective, the distribution sector and the pharmacy sector are the ones supporting the growth," the company stated. At the start of the month, Zetes' expanded its activities in the pharmaceutical sector by launching a new datamatrix marking, control and serialisation solution which it claims will "help drug manufacturers across Europe comply with new and incoming legislation regarding the identification of secondary packaging of medical goods". The solution ensures the accurate affixing of datamatrix codes, either directly on the package (coding or marking) or via real-time printed labels, which is designed to  minimise the chances of counterfeiting occurring. In addition, the tool also handles serialisation, tamper-evident sealing, and labelling with pre-printed labels, with Zetes claiming it has been designed to integrate with high speed production lines, which will ensure secure marking and inspection and the storage of data of up to 500 packs per minute.

Alain Wirtz, chief executive of Zetes, said that improving traceability is an "increasing challenge" for many manufacturers, with one drug manufacturer in France already utilising the news system to print the datamatrix codes needed to comply with the country's CIP13 batch-level coding requirements. He explained: "Our solution has been developed based upon our extensive experience with designing, building and implementing print and labelling systems, which are already used by many drug manufacturers at the end of their  production lines." Mr Wirtz said that the counterfeiting of medicinal products is an "increasing threat to public health and safety", and pointed out that the European Federation of Pharmaceutical Industries and  Associations is working on an end-to-end product verification system, based on mass serialisation.

By identifying each individual product, he noted that the industry may be able to combat counterfeiting, reduce theft and derivations, and thus ensure improved patient safety. With industry leaders keen to identify the best way of achieving a smooth transition to mass serialisation and keep apace of the rapidly-evolving  authentication, serialisation and track and trace systems in order to reduce counterfeiting and remain competitive, developments such as those being made by Zetes are likely to continue to increase in volume in the coming months and years.

Cost-effective supply chain security and compulsory safety features are industry buzzwords and both will play a key role in serialisation and traceability in the near future.

Want to learn more about developments and technologies in pharmaceutical authentication?
Visit our Download Center for more articles, whitepapers and interviews:
http://bit.ly/track-and-trace

Mittwoch, 7. September 2011

Der Pharma-Markt nach dem AMNOG

Yvonne Bruchhausen, Leiterin Key Account Solutions bei GlaxoSmithKline Deutschland, sprach exklusiv mit IQPC über den aktuellen Status bei Direktverträgen, entscheidende Kriterien für erfolgreich abgeschlossene Verträge, und wie sich der Markt durch das Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) verändern wird. Das AMNOG soll künftig direkte Verhandlungen von Herstellern und Kassen ermöglichen.

Das Interview wurde als Video aufgezeichnet. Starten Sie das Video hier.

Dienstag, 6. September 2011

Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking

In present times, legislative and regulatory measures are of great importance in the pharmaceutical industry. We always take it for granted that pharmaceutical products around us are appropriately manufactured, properly labelled and safe for consumption. This trust is due to the fact that we believe these pharmaceutical products are manufactured and tested under strict regulations and laws formed by the government. It is only this way they can reach the patient or the end user. However, this view is quite far from the real truth. The real legislative and regulatory infrastructure was first given proper shape in 1927 when the FDA (Food & Drug Administration) was formed. These days one of the most important aspects concerning pharmaceutical industry is pharmaceutical product tracking and the laws and regulations dealing with this aspect. A good and efficient system meant for tracking and tracing pharmaceutical products will eventually help in detecting the counterfeit medicines. Moreover, this system also helps in a better control of supply chain and also the proper identification of pharmaceutical products even if recalls are required. However, counterfeit medicines are by and large still the biggest challenge to be dealt with. It is to be noted that fraud and counterfeiting are the most risky factors when we are talking about the safety of pharmaceuticals.

Developments in pharmaceutical product tracking in the USA

In the year 2004, the FDA, in its first report dealing with the problem of counterfeit drugs, emphasised the importance of electronic track & trace technology to ensure the safety of the supply of medicines. The FDA implemented the use of RFID (Radio Frequency Identification) technology to be the standard technology in tracking and tracing pharmaceutical products in 2007. RFID is a kind of technology which by using radio frequencies allows the automatic identification & data capture of a product. Under this technology, usually a unique or an exclusive type of identifier and some additional information is attached with the product using a device called as microchip.

This information can be read and interpreted by using a wireless device called an RFID reader, which uses radio frequencies to read an electronic tag attached to the product and identifies this unique identifier. However, implementing such a system in the pharmaceutical industry, some basic industry standards, as well as the necessary IT infrastructure first had to be set up. The RFID system will now be implemented under the Prescription Drug Marketing Act (1987). Although strongly favoured by the FDA and the US pharmaceutical industry, there are some issues involved with using RFID technology. First of all, it is quite costly and another issue is regarding the patient’s privacy. Further, in the USA, some medicines are packed in smaller packs by the pharmacists and in these cases a bar code system and RFID does not allow total control of the product. In Europe, there is a unit of use pack which allows the total control of the supply chain. Moreover, most companies are still hesitant in attaching the RFID tags to pharmaceutical products as they are still waiting for maturing of technical standards. The war against the counterfeit medicines is slowly shifting into full gear in the USA, as the government has also formed a new law making this counterfeit medicines issue a criminal offence with the offender facing punishment of up to life imprisonment, depending on the severity of patient suffering.

Product tracking for supply chain efficiency and protection

In present times, pharmaceutical companies and regulatory agencies are very concerned about fraud and counterfeiting issues in the whole supply chain network especially when the medicines are getting expensive. The government plays a very important role in protecting people from counterfeit drugs by introducing regulations and laws covering the whole pharmaceuticals supply chain which puts a check at each and every stage, starting right from the production facility. In the last five years, the technology used for tracking pharmaceutical products has been developed and upgraded many times due to technological advancements. This has led to many possibilities like tracing and tracking these products down to an item level. RFID technology, scanning technology, 2D matrix codes and sophisticated databases have enormously helped in offering more accountability all over the supply chain.

Therefore, the emergence of track & trace systems for drugs is becoming a necessity and due to this reason this has become a legal requirement in many countries. Different methods are given importance in different countries depending on the requirements and packaging standards of drugs. While in Europe 2D data matrix codes are given preference, in the USA, RFID technology is the preferred one. It is to be noted that RFID is considered to have more advantages than the other technologies as it can also monitor other conditions like temperature when drugs are transported from one place to another. So in order for the supply chain to be robust, these tracking and tracing technologies have to be in place.

Download the full article for free:

Handling des Datenvolumens im 2-SM
Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking
Depending upon the various types of drug packs and formats, there are various problems associated with the tracking and tracing of pharmaceutical products especially when tracking a single item. In Europe, blister packs are used, while in the USA containers of tablets are used and the information is coded on the container, not on a per item kind of basis.

Freitag, 2. September 2011

Effective Information Management to Aid Regulatory Submissions


Konferenz Regulatorisches (e)Dokumentenmanagement Pharma
 
Article
Effective Information Management to Aid Regulatory Submissions: What Do You Do to Make it Work in Practice?
Pharmaceutical companies are placing even more importance on the pharma regulatory aspects of data and information systems. Neil Gow, Head of Records Management for UCB, joins us to discuss the challenges to efficient and effective mnagement in pharma and biotech.

Read the full article HERE !

Donnerstag, 1. September 2011

Pharma Sales Force: Rückblick & Eindrücke aus 2010

Zum sechsten Mal fand die Pharma Sales Force im Oktober 2010 in Berlin statt. Über 100 Teilnehmer haben die Pharma Sales Force 2010 genutzt, um sich über aktuelle Herausforderungen im Pharmavertrieb auszutauschen.

Informationsreiche Kongresstage
Mehr als 30 Fachvorträge, Round-Table-Diskussionen und Workshops zu den Themen Market Access, Marketing und Vertrieb boten die Möglichkeit zum Benchmarking der eigenen Konzepte und Strategien.




Intensives Networking
Wie gewohnt kam auch das Networking nicht zu kurz: Der Kongress bot zum offenen Austausch ausgiebige Gelegenheiten an. Und auch im Anschluss konnten Themen und Gespräche in angenehmer Atmosphäre vertieft werden.



Kundenstimmen

"Wenn du Sales-Verantwortung hast – hingehen!"

Michael Esther, Verkaufsleiter Deutschland BU Onkologie & Hospital, Riemser Arzneimittel AG


"Hochwertige Konferenz mit vielen Entscheidern, die fest in unserem Marketingplan gebucht ist"

Roger Schramm, Account Executive Retail & Manufacturing, SPSS GmbH

"Geballtes Know-how auf hohem Niveau."
Matthias Diessel, head of Business Development, easyApotheke AG
------------------------------------------------------------------------

Mehr Eindrücke von der Pharma Sales Force 2010 gibt es in dem Impressionen-Video.

Sie wollen die Pharma Sales Force 2011 auf keinen Fall verpassen? Mehr Informationen sowie das exklusive Programm finden Sie hier.

Mittwoch, 24. August 2011

Was sind die grundsätzlichen Unterschiede in der Beratungskompetenz von Drogerie und Apotheke?

IQPC traf Jens Apermann exklusiv zum Interview. Jens Apermann ist Geschäftsführer der Iwan Budnikowsky Marketing GmbH. In dem Interview spricht er über Apothekenexklusivität und das Projekt Budni-Partner-Apotheken.


Die BUDNI-Partner-Apotheken arbeiten bereits seit 2003 im Netzwerk der Hamburger Partner-Apotheken zusammen. Durch die zusätzliche Kooperation mit BUDNIKOWSKY erhalten die Apotheken exklusiven Zugang zum erfolgreichsten Kundenbindungsprogramm Hamburgs, der BUDNI KARTE.

Das Interview wurde als Podcast aufgezeichnet. Klicken Sie hier um das Interview anzuhören.

Montag, 22. August 2011

Modified ecstasy 'attacks blood cancers'



Modified ecstasy could one day have a role to play in fighting some blood cancers, according to scientists.
Ecstasy is known to kill some cancer cells, but scientists have increased its effectiveness 100-fold, they said in Investigational New Drugs journal.

Their early study showed all leukaemia, lymphoma and myeloma cells could be killed in a test tube, but any treatment would be a decade away.

A charity said the findings were a "significant step forward".

In 2006, a research team at the University of Birmingham showed that ecstasy and anti-depressants such as Prozac had the potential to stop cancers growing.

The problem was that it needed doses so high they would have been fatal if given to people.

The researchers, in collaboration with the University of Western Australia, have chemically re-engineered ecstasy by taking some atoms away and putting new ones in their place.

One variant increased cancer-fighting effectiveness 100-fold. It means that if 100g of un-modified ecstasy was needed to get the desired effect, only 1g of the modified ecstasy would be needed to have the same effect.
Scientists say this also reduced the toxic effect on the brain.

Lead researcher Professor John Gordon, from the University of Birmingham, told the BBC: "Against the cancers, particularly the leukaemia, the lymphoma and the myeloma, where we've tested these new compounds we can wipe out 100% of the cancer cells in some cases.

"We would really need to pinpoint which are the most sensitive cases, but it has the potential to wipe out all the cancer cells in those examples.

"This is in the test tube, it could be different in the patient, but for now it's quite exciting."

'Soapy' cells
 
It is believed that the drug is attracted to the fat in the membranes of the cancerous cells.

Researchers think it makes the cells "a bit more soapy", which can break down the membrane and kill the cell.
They said cancerous cells were more susceptible than normal, healthy ones.

However, doctors are not going to start prescribing modified ecstasy to cancer patients in the near future.
The research has been demonstrated only in samples in a test tube. Animals studies and clinical trials would be needed before prescribing a drug could be considered.

First, however, chemists in the UK and Australia are going to try to tweak the modified ecstasy even further as they think it can be made even more potent.

'Genuinely exciting'
 
If everything is successful, a drug is still at least a decade away.

Dr David Grant, scientific director of the charity Leukaemia and Lymphoma Research, said: "The prospect of being able to target blood cancer with a drug derived from ecstasy is a genuinely exciting proposition.

"Many types of lymphoma remain hard to treat and non-toxic drugs which are both effective and have few side effects are desperately needed.

"Further work is required but this research is a significant step forward in developing a potential new cancer drug."

Freitag, 19. August 2011

Pharma Sales Force "Sommerspecial"

"Zwei kommen - Einer zahlt!"

Melden Sie sich und Ihren Kollegen jetzt mit dem "2 for 1"-Ticket zum Jahreskongress an. Egal, welches Paket Sie zu zweit buchen - Sie sparen einen gesamten Eintrittpreis!

Aber Achtung! Das Sommerspecial-Angebot gilt nur bis zum 31. August 2011!

TOPTHEMEN PHARMA SALES FORCE 2011

Diskutieren Sie mit Experten der Branche Konzepte und Entwicklungen im Pharmavertrieb. Die diesjährigen Kongress-Schwerpunkte sind:

- Auf der Suche nach dem New Commercial Model - ist Collaborative Healthcare die Lösung?

- Effizienz- und Wertschöpfungspotenziale im Vertrieb realisieren: Welche Konzepte sind zielführend?

- Market Access und frühe Nutzenbewertung - wie soll sich die Industrie auf die Konsequenzen von AMNOG vorbereiten?

- CRM, Closed Loop Marketing, Social Media: Wo passt welche Multi Channel Strategie?

- Key Account Management: Hat die Umstellung auf KAM-Strukturen die gewünschten Erfolge gebracht?

Weitere Informationen finden Sie hier.


Donnerstag, 18. August 2011

Dogs Sniff Out Lung Cancer in Humans

Study Shows Some Dogs Can Be Trained to Identify Lung   Cancer When They Sniff a Person's Breath

Close up of dogs nose By Brenda Goodman, WebMD Health News,Reviewed by Laura J. Martin, MD
Aug. 17, 2011

German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.

In its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.

"This is the holy grail," says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.

"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers," says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors. He was not involved in the research.

Recently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.

But that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.

Checking for Lung Cancer

The new study, which is published in the European Respiratory Journal, found that four trained dogs -- two German shepherds, an Australian shepherd, and a Labrador retriever -- correctly identified cancer in 71 of 100 samples from lung cancer patients.

They also ruled out cancer in 372 out of 400 samples that were known not to have cancer, giving them a very low rate of false positives, about 7%.

"The surprising result of our study is the very high specificity of our dogs to identify lung cancer," says study researcher Thorsten Walles, MD, a lung surgeon at Schillerhoehe Hospital in Gerlingen, Germany.
"It even surpasses the combination of chest computed tomography (CT) scan and bronchoscopy, which is an invasive procedure that needs some form of anesthesia," Walles tells WebMD in an email.

Doctors have previously reported cases in which dogs have alerted their owners to undiagnosed skin, breast, and lung cancers by repeatedly pawing or nosing an affected body part. Some dogs have even been trained to smell low blood sugar levels in people who have diabetes.

But dogs have had more mixed success in carefully controlled studies, where samples from healthy people and sick people have been mixed.

A study published in BMJ in 2004 found that dogs correctly identified bladder cancer an average of about 40% of the time, a rate that was better than the 14% accuracy that could be expected by chance, but was lower than available tests.

But in June, researchers in Japan reported that dogs could detect the presence of colon cancer in human breath and stool samples with nearly 90% accuracy, a success rate only slightly lower than colonoscopy.

Checking for Lung Cancer continued...

The length of time the dogs are trained may be an important difference between the studies, Walles says. In his study, the four dogs were trained for nine months. Other studies have used dogs trained for as little as three weeks.

The kind of sample the dogs are asked to smell -- urine, breath, blood, or stool -- may also influence the results, he says.

In his study, 220 volunteers -- 110 who were healthy, 60 who had lung cancer, and 50 with chronic obstructive pulmonary disease (COPD) -- were asked to exhale into a glass tube filled with fleece.

The tubes were mixed up so neither the dogs' handlers nor two observers who placed the samples on the floor in front of the dogs knew the status of the person they were from, to avoid inadvertently giving the dogs clues about what they should find.

The dogs were presented with five tubes at a time. Only one contained a sample from a person with cancer.
The dogs were trained to lie down and put their nose to the tube if they detected lung cancer.

The dogs appeared to be able to accurately identify the samples from cancer patients, even when they were in very early stages of the disease. And they were able to pick up the scent despite competing odors of cigarette smoke or food on a person's breath.

How Dogs Detect Cancer

Researchers think dogs and other animals are able to smell disease by picking up on minute changes in compounds called volatile organic compounds (VOCs) that comprise chemical signatures in the body.
As many as 4,000 different VOCs, for example, have been identified in human breath.

A dog's sense of smell has been estimated to be 100 to 1,000 times more powerful than a human's, says Gary K. Beauchamp, PhD, director of the Monell Chemical Senses Center in Philadelphia.

"It's not just how sensitive their nose is. It's how they process this into a recognition pattern," Beauchamp says. "The reason dogs can do this is that they're recognizing a complex picture, and that's the big trick, to find out how to mimic that in some sort of device that could be useful for diagnostic purposes in human disease."
Other researchers agree.

Ramalingam says because success rates vary between dogs and between samples, the real value of knowing dogs can detect cancer will likely be in building technology that can reliably repeat what they can do.
"The dogs show that it can be done. We need to find out what the dogs are sniffing so we can do it in a more scientific manner."

Mittwoch, 17. August 2011

How to deal with medicine counterfeiting?

Counterfeiting especially in regards to medicine is not only posing a big problem to the pharma industry, but is also life-threatening for the end-users. What is the best system to combat counterfeits? Is using end-to-end systems or is track'n'trace the answer?

In our download center you can find many free articles, presentations, interviews and whitepapers on this subject, for example:

Handling des Datenvolumens im 2-SM
Securing the Supply Chain to Combat Counterfeit Medicines
Counterfeit medicines present a serious challenge for the pharmaceutical industry. As well as the dangers to public health presented by such drugs, the presence of counterfeit medicines serves to reduce confidence within the pharmaceutical industry as a whole.
Handling des Datenvolumens im 2-SM
Ensuring a Secure and Compliant Pharmaceutical Supply Chain
As pharmaceutical companies keep moving on the path of globalizing their operations and product development, they must be prepared to manage the challenges that are inherent in such a supply chain. The primary challenges include an increase in illicit activities (e.g. counterfeiting, piracy, adultery), increased safety concerns for the consumer, a tough regulatory environment, and an ever increasing degree of complexity on account of globalization.
Handling des Datenvolumens im 2-SM
Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking
Depending upon the various types of drug packs and formats, there are various problems associated with the tracking and tracing of pharmaceutical products especially when tracking a single item. In Europe, blister packs are used, while in the USA containers of tablets are used and the information is coded on the container, not on a per item kind of basis.


Visit the website for more information on this subject: Pharma Track & Trace.

Mittwoch, 10. August 2011

Engineer your way to increased productivity of your sales force

Learn how you can apply Six Sigma to your sales force to increase productivity! In this Profit through Process podcast, Genna Weiss of Six Sigma IQ, speaks with Justin Hitt, Strategic Relations Consultant for JWH Consolidated Inc., who discusses how Six Sigma and other engineering processes can help complement traditional methods of increasing selling productivity and establish accountable, consistent and measurable results for your sales person’s performance.

The complete interview has been recorded as a podcast. You can listen to it here. It is also available as a download here.

Dienstag, 9. August 2011

Pharmabranche zahlt zwei Milliarden Euro

von Maike Telgheder (Handelsblatt)

Vor einem Jahr wurden die Zwangsrabatte auf verschreibungspflichtige Arzneimittel von 6 auf 16 Prozent erhöht. Das hatte Folgen: Die deutsche Pharmaindustrie musste zwei Milliarden Euro Rabatt gewähren.

Die Pharmaindustrie in Deutschland muss in diesem Jahr mehr als zwei Milliarden Euro Rabatt auf ihre verschreibungspflichtigen Medikamente gewähren. Das sind 1,2 Milliarden mehr als noch im vergangenen Jahr, bei einem Branchenumsatz von 18 Milliarden Euro. Das zeigen aktuelle Berechnungen des Marktforschungsinstituts IMS Health, die dem Handelsblatt exklusiv vorliegen. Hintergrund ist die vor einem Jahr in Kraft getretene Regelung, nach der die Zwangsrabatte für verschreibungspflichtige Arzneimittel von 6 auf 16 Prozent erhöht wurden.

In der exklusiv für das Handelsblatt erhobenen Auswertung hat IMS ermittelt, dass im ersten Halbjahr dieses Jahres rund 27 Prozent des Rabattvolumen in Höhe von 1,14 Milliarden Euro auf allein fünf Unternehmen entfällt: Pfizer, Novartis, Roche, MSD und Astra Zeneca mussten den gesetzliche Krankenkassen danach durchschnittlich 60 Millionen Euro Rabatt gewähren.

Aufs Jahr hochgerechnet, müssen die fünf großen Firmen also jeweils mit durchschnittlich 120 Millionen Euro weniger Einnahmen rechnen, bei Deutschlandumsätzen von eine bis drei Milliarden Euro. Die Zwangsrabatte treffen allerdings eine Branche, die gut verdient. Die durchschnittliche Gewinnmarge vor Zinsen und Steuern (EBIT) der 20 weltgrößten Pharmafirmen liegt bei 24 Prozent. Zum Vergleich: Die Automobilindustrie kommt auf 4,6 Prozent.

Montag, 8. August 2011

Exclusive Podcast Series: Preclinical to clinical translation - the "tool" box

In our exclusive three-part podcast series, Prof. Martin Wehling, Managing Director at the University of Heidelberg’s Institute for Experimental & Clinical Pharmacology, speaks about current developments and challenges in translational medicine today.

Follow the links to download the podcast or to listen online:

Interview Martin WehlingInterview Martin WehlingInterview Martin WehlingPreclinical to clinical translation - the “tool box” (Part 1) In part one of our three-part podcast series, Prof. Martin Wehling, Managing Director at the University of Heidelberg’s Institute for Experimental & Clinical Pharmacology, speaks about current developments and challenges in translational medicine today.


Preclinical to clinical translation - the “tool box” (Part 2) In part two of our three-part podcast series, Prof. Wehling speaks about the standardized translational “tool box”, the current efficacy of physiologically based pharmacokinetic modelling (PBPK), and the relevance of biomarkers to translational processes.


Preclinical to clinical translation - the “tool box” (Part 3) In the third and final part of our podcast series on the preclinical to clinical translation tool box, Prof. Wehling gives insight into the role of pharmaceutical industry, joint public-private ventures and the future of Preclinical to clinical translation.

Mittwoch, 3. August 2011

Angewandte Regelung und Optimierung in der Prozessindustrie

Why bother? Bringen Optimierungsprojekte überhaupt was? Und wie berechnet man den Nutzen einer Lösung? In der folgenden 53-Seitigen Präsentation gibt Alexander Horch Antworten, z.B.:

Nutzen gehobener Lösungen - Das Potenzial ist gigantisch.
  • Viele Optimierungen sind noch nicht realisiert.
  • Schätzungen sagen Einsparungen von ca. 5 Billionen USD nur in Nordamerika voraus, wenn alle Regelungen optimal funktionierten.
  • Die Prozessindustrie verändert sich ständig, daher gibt es ständiges Verbesserungspotenzial.
  • Energieeffizienz in der Prozessindustrie war bislang kaum ein Thema. Der Fokus lag auf Maximierung der Produktion.
  • Optimierungen für Teillastbetrieb sind kaum existent.
  • Optimierungsverfahren für neue Produktionsverfahren (z.B. Kunststoffe aus Biomasse) sind noch nicht existent.
  • Vorhandene Anlagen, oft älter als 30 Jahre laufen bei Weitem nicht optimal.

Nutzen gehobener Lösungen - Wann nützt eine Lösung?
  • Einsparung von Einsatz- und Hilfsstoffen
  • Einsparung von Energie, Wasser, …
  • Einsparung von Emissionen (NOx, CO2, CO, SO2, …)
  • Personalentlastung (oft keine direkte Einsparung)
  • Verbesserte Produktqualität
  • Anlagenschonung, verlängerte Laufzeit, größere
  • Wartungsintervalle
  • Verbesserte Produktionsrate
  • Erhöhung der Anlagenverfügbarkeit, Vermeidung von Stillständen
  • Verbesserte Anlagensicherheit
  • Flexibilisierung der Produktion

Laden Sie sich jetzt diese interessante Präsentation für weitere Details herunter:  Angewandte Regelung und Optimierung in der Prozessindustrie


Tip: Interessiert an: Plant Asset Management? Klicken Sie hier für kostenlose Whitepaper, Präsentationen und Artikel.

Dienstag, 2. August 2011

Welche Konsequenzen hat das AMNOG auf die Vetriebsstrategien der deutschen Pharmaindustrie?

Von Seiten der Pharmaindustrie wurde die Entstehung des Arzneimittelneuordnungsgesetzes (AMNOG) kritisch begleitet. Vor allem die Regelungen zur frühen Nutzenbewertung stehen nach wie vor in der Kritik. In einem exklusiven Interview mit IQPC spricht Dr. med. Steffen Wahler, Vice President Clinical Outcomes & Reimbursement bei der Iroko Cardio GmbH, über die Konsequenzen, die die Neuordnung für die Entwicklung innovativer Arzneimittel hat.

Sein bisheriges Fazit zur Umsetzung des neuen Gesetzes fällt eher kritisch aus: „Es ist noch nichts passiert, da noch kein einziges Produkt durch das Raster des AMNOG endgültig gelaufen ist und man von daher keine endgültigen Aussagen machen kann“. Außerdem seien die an die Industrie gestellten Anforderungen, um ein Produkt auf den deutschen Markt zu bringen, sehr komplex. Darüber hinaus gibt es starke formale und inhaltliche Abweichungen zum europäischen und weltweiten Verständnis von „Dossiers“. Für den nationalen Markt seien die vielen üblichen Sonderaufwendungen im Zuge dessen für eine sinnvolle Preisfindung wenig hilfreich.

Des Weiteren spricht Dr. Wahler über potenzielle Probleme in der Preisverhandlung zwischen Industrie und GKV-Spitzenverband. So gibt er schließlich Hinweise für eine gelungene Unternehmensaufstellung, damit die Chancen des AMNOG zum Tragen kommen.

Um das gesamte Interview zu hören, klicken Sie hier. Weitere Informationen, Artikel und das ausführliche Konferenzprogramm zum 7. Jahresforum Pharma Sales Force 2011 finden Sie auf der Website.

Dienstag, 26. Juli 2011

Han Steutel (B-MS) über neue Kommerzialisierungsmodelle

Han Steutel ist European Vice President & General Manager Germany bei Bristol-Myers Squibb (B-MS). Er begann seine Karriere 1987 bei AstraZeneca in den Niederlanden, seit 1999 ist er bei B-MS beschäftigt.

Bevor er 2008 in Deutschland die Geschäftsführung übernahm, leitete Han Steutel fünf Jahre als General Manager die niederländische B-MS Zentrale. Neben seiner Tätigkeit in dem amerikanischen Biopharmaunternehmen war er in führender Position in einer Reihe von Industrieverbänden aktiv, darunter als Vorsitzender der Pharmagruppe der American Chamber of Commerce der Niederlande und später als Präsident des niederländischen Verbandes der Forschenden Arzneimittelunternehmen Nefarma.

Han Steutel ist seit 2009 im Vorstand des Deutschen Verbandes der forschenden Pharma-Unternehmen, vfa, vertreten.

Auf der Pharma Sales Force 2011 wird Han Steutel mit anderen CEO-Kollegen "Das New Commercial Model - Der Pharmavertrieb zwischen Herausforderungen, Chancen und Risiken" diskutieren. Erfahren Sie mehr hier.

Dienstag, 19. Juli 2011

Pharma: Rahmenbedingungen und Zukunftschancen für Rabattverträge

Dr. Christopher Hermann, Stellv. Vorstandsvorsitzender, AOK Baden-Württemberg, gibt einen Einblick in die Rahmenbedingungen und Zukunftschancen für Rabattverträge vor dem Hintergrund des AMNOG.


Welche Auswirkungen sind durch die Anwendung des Kartellrechts bei Rabattverträgen zu befürchten? Welches sind die negativen Konsequenzen der Mehrkostenregelungen? Dies und vieles mehr sind Themen des Interviews.

Das Interview ist als Video verfügbar. Dieses sehen Sie hier.

Freitag, 15. Juli 2011

Wie sollten Unternehmen sich aufstellen, damit die Chances des AMNOG zum Tragen kommen?

Dr. Med. Steffen Wahler, VP Clinical Outcome & Reimbursement bei Iroko Cardio International, spicht exklusiv mit IQPC über die Konsequenzen der Regelungen zur frühen Nutzenbewertung für die Entwicklung neuer Arzneimittel sowie die Auswirkungen des AMNOG auf das Vertriebsmodell der Pharmaindustrie. Das ausführliche Gespräch wurde als Podcast aufgezeichnet.



Der Podcast kann kostenlos hier angehört und gedownloaded werden.

Sie möchten Herrn Dr. Steffen Wahler gerne live erleben? Besuchen Sie die Pharma Sales Force 2011, wo Dr. Steffen Wahler und viele weitere namhafte Referenten sprechen werden. Das Konferenz-Programm sowie weitere Informationen finden Sie hier.

Donnerstag, 14. Juli 2011

Pharma Execs Confess Innovation Is Lacking

An article By Ed Silverman // (Pharmalot
 
When the going gets tough, do the tough know now to innovate? Apparently not. At least that’s what a bunch of pharma execs confess in a new survey that finds only 54 percent - including those who admit to having poor or ineffective innovation strategies - consider innovation to be a leading priority. And only 49 percent rank their overall innovation strategy as just moderately effective, at best.

More specifically, improving innovation was cited as the single most important priority that will define success by 16 percent, while 38 mentioned this is a one of a handful of top priorities. Interestingly, 26 percent reported that change is important, but really just one priority among many others. And 11 percent say change would be good, but it is not a priority. And 7 percent say ‘why change?’

Meanwhile, just 47 percent report their R&D model is capable of meeting corporate needs and only 42 percent say their strategy is more than moderately successful at replenishing the pipeline. These sobering results reflect comments from 282 senior execs, including 58 percent from the c-suite, by the Economist Intelligence Unit and was done at the behest of Quintiles, the clinical research organization.

“In any other industry you can measure using metrics, but you can’t really do that in this industry,” Peter Hongaard Andersen, exec vp for research at Lundbeck, tells the questionnaires. Instead, potential improvements need to be assessed against non-tangible criteria, such as measuring the quality of efforts before knowing if a pay off exists. “That is why we are all struggling to get this right.”

But what are the impediments to improving innovation? Not surprisingly 47 percent cited cost as a leading barrier, followed by 38 percent who pointed to the time involved in product development and 33 percent who fault regulatory restrictions. However, cultural attachment to existing ways and a lack of talent were cited by 24 percent. And difficult corporate structures were mentioned by 21 percent.

“Right now the industry is very much driven by fear rather than by ambition,” Paion ceo Wolfgang Soehngen tells the questionnaires. He acknowledges that there are legitimate issues that make innovation difficult to achieve. But, he adds, these are “partially fact, partially an excuse.”

The survey found that drugmakers and biotechs are experimenting with a number of possible improvements, but none of these strategies is becoming widely popular within their organizations. In fact, Nine different ideas have each been adopted at more than 20 percent of the companies, but the most popular were only taken on by one-third of the respondents.


When it comes to finding ideas, here’s an interesting contrast: over the last three years, 59 percent of employees in clinical development at device makers, generic makers and service providers cite doctors and medical experts as sources, while 41 percent point to academic research and 35 percent named patients and patients groups. The rest of the employees have differing views: 51 percent cited internal R&D; 44 percent named existing intellectual property and 34 percent pointed to doctors.

In biopharma, academic research was cited as the second most common source of ideas over the coming three years - 38 percent, to be exact, while only 24 percent of other employees pointed to such research. Internal R&D remains the leading source of innovation as a whole, cited by 60 percent, but over the next three years, just 46 percent of the execs say internal R&D will be a good source.

Meanwhile 63 percent of those who believe they have effective innovation programs say they are successfully using open innovation, compared with 35 percent of the rest of the respondents. Which barriers are mentioned? A lack of certainty over the resulting intellectual property, difficulty in coordinating the process, and research costs that can impede effective open collaboration.

When asked how well their companies use data to support its product innovation, both internal and external data - 34 percent say they use internal data very well, but only 21 percent acknowledged making similar use of external data. All totaled, 51 percent say sharing data across companies is either very useful or simply useful.

By the way, over the last three years, 37 percent of execs who say their innovation programs are very effective have adopted new technology to access and mine data, and 33 percent have invested in technology to speed the way that drug candidates are filtered. This compares with 22 percent of those who do not describe their innovation efforts as effective.

The findings maintain this correlates to success - 67 percent of the so-called innovation leaders say they use internal company data to support innovation very well, compared with 25 percent of the rest; and 38 percent say the same about external data, compared with 17 percent among the others.

But how does one go about creating a good innovation environment? Consider rewards. More of the self-proclaimed innovation leaders offer financial rewards for contributions - 53 percent compared with 29 percent. And 47 percent of those with who rate their innovation systems as very effective also provide recognition for contributions to innovation, compared with 39 percent of the others.

Mittwoch, 6. Juli 2011

Building a compound management facility: The intergration challenge - an exclusive interview.

Building a compound management facility - The intergration challenge - Reiner Dieden PhD in an exclusive interview

Reiner Dieden PhD, Analyst and Physical Chemistry and Logistics Director from UCB, joins Helen Winsor Pharma IQ, to report on the development of a compound management facility at The University of Bonn.

Listen to this Podcast online now; alternatively download it here.

Tip: Interested in learning more about Compound Management and Compound Libraries? Click here.

Dienstag, 5. Juli 2011

Green Solutions for Cold Chains

As the world's focus shifts towards reducing carbon emissions, the pharmaceutical industry finds itself facing a dilemma in maintaining strict safety standards while improving its environmental credentials. One of the key areas where this must be met head on is in the energy intensive field of temperature controlled distribution, where a breach in the cold chain could severely reduce the efficacy of a drug and as such have a negative effect on patient health.

Speaking to Next Generation Pharmaceuticals, Richard Harrop, commercial and technical manager of SCA Cool Logistics, said: "Environmental accountability is already bringing considerations regarding recyclability, carbon emissions and energy cost. Cold chain is one part that can be re-evaluated from a green standpoint."

Packaging solutions

As Harrop explained, there are already a number of greener solutions on the market which allow companies to reduce the carbon footprint of their cold chain.

Biodegradable and recyclable packaging materials are increasingly being looked at to provide more environmentally friendly solutions, which do not compromise on the safety of the products.

GREENBOX was one example provided by Harrop, which is made from 100 percent recyclable materials and can be reused, meaning fewer boxes have to be produced, cutting the amount of carbon produced by manufacturing processes. Reducing the overall size and weight of the packaging is also been seen as a way of making cold chains greener, while reducing transport costs.


"Blister packages, for example, are shipped as fully loaded packages, ready for immediate distribution by pharmacists." 
Dr. Ted Lithgow, president, MWV Healthcare
 

"Blister packages, for example, are shipped as fully loaded packages, ready for immediate distribution by pharmacists. Additionally, from a structural design perspective, they can be stacked, stored, and shipped more efficiently than standard amber vials," Dr. Ted Lithgow, president, MWV Healthcare, writing for Healthcare Packaging, explained.

Suppliers to major pharmaceutical firms should also take note of this trend. The Carbon Disclosure Project supply chain report released last year revealed suppliers are increasingly being expected to demonstrate their environmental credentials.

Read more about implementing greener cold chain solutions, download the full article here.


Tip: Download free whitepapers and articles for Cold Chain and Cool Chain transportation, click here.

Montag, 4. Juli 2011

Keeping the Pharma Sales Door Open

Daniel Schick, Executive Director, Commercial Affairs & Key Account Management bei Janssen-Cilag, spricht mit Pharma IQ über die aktuellen Herausforderungen im Pharma Sales. Er spricht über die drastischen Veränderungen im deutschen Gesundheitsmarkt und die daraus resultierenden Trends, die jetzt beobachtet werden.


Das Interview wurde als Podcast aufgezeichnet und kann hier runtergeladen oder direkt angehört werden.